GSK Sales Decline By 2% In Q3, But Witty Sees Light At The End Of The Tunnel
This article was originally published in The Pink Sheet Daily
Executive Summary
Pandemic flu products and Avandia year-on-year comparisons mask progress at GlaxoSmithKline.